DMRA
Live chart
What they do
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia.
For information only · Important disclosures
Grades vs sector
No sector grades for DMRA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | -0.37 | -0.39 | -5.4% |
| 2025-03-19 | -2.82 | -5.00 | -77.3% |
| 2024-11-01 | -3.70 | -3.39 | +8.4% |
| 2024-08-12 | -6.00 | -5.00 | +16.7% |
| 2024-04-29 | -4.25 | -5.00 | -17.6% |
| 2024-03-08 | -6.25 | -4.76 | +23.8% |
| 2023-11-06 | -12.12 | -4.99 | +58.9% |
| 2023-07-31 | -14.67 | -10.25 | +30.1% |
Insider trades
$252.9K
–
Stats refreshed 2026-10-21 17:59:35 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026